医学
万古霉素
不利影响
青霉素
肾毒性
耳毒性
抗生素
重症监护医学
中性粒细胞减少症
肺炎链球菌
金黄色葡萄球菌
头孢菌素
内科学
毒性
微生物学
化疗
细菌
生物
顺铂
遗传学
作者
Felipe Ribeiro Bruniera,Felipe Ferreira,L R M Saviolli,Marcelo Rodrigues Bacci,David Feder,Mavilde da Luz Gonçalves Pedreira,Maria Angélica Sorgini Peterlini,Lígia Ajaime Azzalis,Virgínia Junqueira,Fernando Luiz Affonso Fonseca
出处
期刊:PubMed
日期:2015-02-01
卷期号:19 (4): 694-700
被引量:240
摘要
Vancomycin (VCM) is a tricyclic glycopeptide antibiotic produced by Streptococcus orientalis. Widely used in hospitals, it is indicated to fight severe infections caused by Gram-positive bacteria, especially with the advent of MRSA (methicillin-resistant Staphylococcus aureus), penicillin-resistant pneumococci among others. Furthermore, it is indicated for the treatment of patients allergic to penicillins and cephalosporins. Dose recommendations, dilution rates and types of infusion are controversial and also result in toxic effects. Aim of this paper was to perform a literature review showing the therapeutic and adverse effects of vancomycin.This is a literature review of recent articles published on MEDLINE and SciELO databases in English, Portuguese and Spanish.The main adverse effects of vancomycin are: hypotension, phlebitis, nephrotoxicity, ototoxicity, hypersensitivity reactions, red man syndrome, neutropenia, chills, fever, interstitial nephritis.The use of vancomycin is still very common; however, inadequate doses and prolonged therapy pose a risk of increasing minimum inhibitory concentrations (MICs), resulting in subtherapeutic levels, treatment failures and toxicity. Therefore, further studies should be conducted to optimize the administration of vancomycin, monitoring treatments from the beginning in order to ensure a safe and effective use of the drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI